NasdaqCM:PLSEMedical Equipment
Pulse Biosciences (PLSE) Passes AF Study Milestone As Investors Weigh An Overvalued Narrative
Pulse Biosciences (PLSE) drew investor attention after announcing that its NANOPULSE-AF Study of the nPulse System has quickly passed the enrollment midpoint, highlighting strong investigator participation and interest in its nanoPFA approach to atrial fibrillation.
See our latest analysis for Pulse Biosciences.
The NANOPULSE-AF milestone comes alongside strong share price momentum, with a 7 day share price return of 16.21% and a 90 day share price return of 68.65%. Over longer periods, total...